{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-333821","form_type":"8-K","ticker":"EYPT","cik":"0001314102","company_name":"EyePoint, Inc.","filed_at":"2026-08-05T11:05:22+00:00","discovered_at":"2026-08-05T11:10:00.421066+00:00","generated_at":"2026-08-05T11:10:50.330216+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"EyePoint Q2 net loss $94.5M ($1.09/sh); cash $180M; LUGANO data expected August 2026","bullets":["Net loss $94.5M vs $59.4M YoY; revenue $0.5M vs $5.3M.","Cash and investments $180M as of June 30, 2026, down from $223M at March 31, 2026.","LUGANO Phase 3 wet AMD topline data expected in August 2026; LUCIA data Q4 2026.","DME Phase 3 trials COMO and CAPRI fully enrolled (over 480 patients); topline data Q4 2027.","Appointed Tarek S. Hassan, M.D., as Chief Strategic Science Officer in July 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-333821","json":"https://secwatch.observer/filing/0001193125-26-333821.json","markdown":"https://secwatch.observer/filing/0001193125-26-333821.md","text":"https://secwatch.observer/filing/0001193125-26-333821.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1314102/000119312526333821/0001193125-26-333821-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1314102/000119312526333821/eypt-20260805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-05T11:10:50.330216+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}